Gaius HR AG

Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. With 29,000 employees across 110 countries, we translate unique clinical, medical affairs and commercial insights into outcomes that address modern market realities. Our unique integrated model combines clinical development, medical affairs, and commercial expertise to support biopharmaceutical companies from early-phase development through product launch and beyond. We have demonstrated exceptional impact in the industry, having helped develop or commercialize 96% of novel oncology drugs approved by the FDA and 93% of oncology products granted marketing authorization by the EMA in recent five-year periods. Whether supporting customers through a Functional Service Provider partnership or a Full-Service environment, our passionate problem solvers collaborate to innovate and accelerate the delivery of therapies to patients worldwide.

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. The company’s work centers on degrading proteins - 'Degrading Proteins, Making Medicines' - and advancing precision approaches that target undruggable or inadequately drugged proteins with unprecedented specificity. On its website, the team is described as combining expertise in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics. Monte Rosa’s QuEEN
9 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine is described as using AI-guided chemistry alongside diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs. The company positions this platform as enabling access to a wide-ranging, differentiated target space across multiple therapeutic areas, and references advancing multiple MGD programs through its pipeline. The company is headquartered in Boston, Massachusetts, and also lists a Basel, Switzerland location on its site.

At Novonesis, we believe that solutions rooted in biology are the key to tackling the biggest challenges our world faces. Our team of more than 10,000 colleagues across 30+ industries works together to transform how the world produces, consumes, and lives. We operate with a culture of collaboration and innovation, drawing on over a century of combined expertise from our heritage companies. Our people thrive in an environment where sustainability is not just a goal but a fundamental part of how we work - where every contribution helps build healthier lives and a healthier planet. We are inherently sustainable because we draw from nature, and we embrace the diverse perspectives that drive our innovation forward. Our inclusive culture fosters belonging and respect, ensuring that everyone can bring their authentic selves to work while making meaningful impact. Whether developing enzymes, functional proteins, or microorganisms, we operate with the conviction that biology holds the answers to humanity's most pressing challenges. We empower our teams with real ownership and cross-functional collaboration, optimizing for impact rather than hierarchy.

At ImmunityBio, we're driven by a patient-first culture that guides everything we do. Our team of scientists, doctors, and staff work tirelessly to transform living biological technologies into innovative treatments for cancer and infectious diseases. We believe in empowering the body's own immune system - rather than weakening it - by developing therapies that activate both innate and adaptive immune responses to create durable, complete responses. Our scientific approach centers on a proprietary natural killer cell platform that can be expanded, genetically modified, and cryopreserved. With 27 clinical trials across 13 indications, our lead product ANKTIVA® (N-803) has earned FDA Breakthrough Therapy designation for BCG-unresponsive non-muscle invasive bladder cancer. Founded by Dr. Patrick Soon-Shiong in 2014, we've grown into a clinical-stage biotechnology company with deep expertise in genomics, proteomics, monoclonal antibodies, fusion proteins, vaccines, and autologous and allogeneic cell therapies. Our success is measured not by milestones, but by the quality of life we can offer patients who need these therapies most.